Exagen Inc (NAS:XGN)
$ 2.75 -0.04 (-1.43%) Market Cap: 47.81 Mil Enterprise Value: 47.91 Mil PE Ratio: 0 PB Ratio: 2.72 GF Score: 70/100

Exagen Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript

Mar 23, 2022 / 07:45PM GMT
Release Date Price: $8.75 (+4.42%)
Paul Knight
KeyBanc Capital Markets - Analyst

Hi, it's Paul Knight, the analyst in life science and diagnostics at KeyBanc. Thanks for being here. (Conference Instructions)

We have Ron Rocca, CEO of Exagen; and Kamal Adawi, Chief Financial Officer. I thought, Ron, if you could provide -- I don't know if you have a slideshow, but or -- just a little bit of an intro for those not familiar with Exagen.

Ron Rocca
Exagen Inc. - President & CEO

Sure. And we have slides.

Paul Knight
KeyBanc Capital Markets - Analyst

Okay.

Ron Rocca
Exagen Inc. - President & CEO

We have slides, but I think it's better if I just talk about it. So we are an autoimmune-focused company, and what that means is strictly with the rheumatologist. Our strategy, our mission if you will, is to own the hilltop. We have a very experienced executive team. And we find that that's the best way to go to market, is to have multiple assets for one specialty category and be able to deliver

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot